NasdaqGS:ALNYBiotechs
Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise
Alnylam Pharmaceuticals (NasdaqGS:ALNY) reports its first full year of profitability, supported by its TTR franchise.
The company introduces a new RNAi manufacturing platform aimed at supporting its growing portfolio of RNA targeted medicines.
Alnylam enters new industry partnerships that expand its presence across RNA therapeutics and drug discovery.
For investors watching RNA based medicines, Alnylam sits at the center of a maturing part of biotech with an approved TTR franchise and a...